Challenges in the clinical measurement of ocular surface disease in glaucoma patients

References

• McKinnonSJGoldbergLDPeeplesPWaltJGBramleyTJCurrent management of glaucoma and the need for complete therapyAm J Manag Care2008141 SupplS20S2718284312
   PubMedGoogle Scholar
• BaudouinCPisellaPJFillacierKOcular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studiesOphthalmology1999106355656310080214
   PubMed Web of Science ®Google Scholar
• BaudouinCHamardPLiangHCreuzot-GarcherCBensoussanLBrignoleFConjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long termOphthalmology2004111122186219215582072
   PubMed Web of Science ®Google Scholar
• RossiGCTinelliCPasinettiGMMilanoGBianchiPEDry eye syndrome-related quality of life in glaucoma patientsEur J Ophthalmol200919457257919551671
   PubMed Web of Science ®Google Scholar
• LeungEWMedeirosFAWeinrebRNPrevalence of ocular surface disease in glaucoma patientsJ Glaucoma200817535035518703943
   PubMed Web of Science ®Google Scholar
• FechtnerRDGodfreyDGBudenzDStewartJAStewartWCJasekMCPrevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medicationsCornea201029661862120386433
   PubMed Web of Science ®Google Scholar
• PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBr J Ophthalmol200286441842311914211
   PubMed Web of Science ®Google Scholar
• JaenenNBaudouinCPouliquenPManniGFigueiredoAZeyenTOcular symptoms and signs with preserved and preservative-free glaucoma medicationsEur J Ophthalmol200717334134917534814
   PubMed Web of Science ®Google Scholar
• NovackGDEvansRCommercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilizationJ Glaucoma200110648348611740219
   PubMed Web of Science ®Google Scholar
• SchwartzGFKotakSMardekianJFainJMIncidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: Retrospective analysis of three medical/pharmacy claims databasesBMC Ophthalmol2011111421672240
   PubMed Web of Science ®Google Scholar
• ErbCGastUSchremmerDGerman register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eyeGraefes Arch Clin Exp Ophthalmol2008246111593160118648841
   PubMed Web of Science ®Google Scholar
• SchaumbergDADanaRBuringJESullivanDAPrevalence of dry eye disease among US men: estimates from the Physicians’ Health StudiesArch Ophthalmol2009127676376819506195
   PubMedGoogle Scholar
• SchaumbergDASullivanDABuringJEDanaMRPrevalence of dry eye syndrome among US womenAm J Ophthalmol2003136231832612888056
   PubMed Web of Science ®Google Scholar
• Detry-MorelMSide effects of glaucoma medicationsBull Soc Belge Ophtalmol2006299274016681086
   PubMedGoogle Scholar
• BaudouinCLabbeALiangHPaulyABrignole-BaudouinFPreservatives in eyedrops: the good, the bad and the uglyProg Retin Eye Res201029431233420302969
   PubMed Web of Science ®Google Scholar
• YeeRWThe effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a reviewCurr Opin Ophthalmol200718213413917301615
   PubMed Web of Science ®Google Scholar
• ChampeauEJEdelhauserHFEffect of ophthalmic preservatives on the ocular surface: conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconateHollyFLambertsDMacKeenDThe Preocular Tear Film in Health, Disease, and Contact Lens WearLubbock, TXDry Eye Institute, Inc1986292302
   Google Scholar
• KaurIPLalSRanaCKakkarSSinghHOcular preservatives: associated risks and newer optionsCutan Ocul Toxicol20092839310319505226
   PubMed Web of Science ®Google Scholar
• PaulyAMeloniMBrignole-BaudouinFWarnetJMBaudouinCMultiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damageInvest Ophthalmol Vis Sci20095041644165219168896
   PubMed Web of Science ®Google Scholar
• UematsuMKumagamiTKusanoMAcute corneal epithelial change after instillation of benzalkonium chloride evaluated using a newly developed in vivo corneal transepithelial electric resistance measurement methodOphthalmic Res200739630831417957130
   PubMed Web of Science ®Google Scholar
• KusanoMUematsuMKumagamiTSasakiHKitaokaTEvaluation of acute corneal barrier change induced by topically applied preservatives using corneal transepithelial electric resistance in vivoCornea2010291808519770721
   PubMed Web of Science ®Google Scholar
• BaudouinCRianchoLWarnetJMBrignoleFIn vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprostInvest Ophthalmol Vis Sci20074894123412817724196
   PubMed Web of Science ®Google Scholar
• De Saint JeanMBrignoleFBringuierAFBauchetAFeldmannGBaudouinCEffects of benzalkonium chloride on growth and survival of Chang conjunctival cellsInvest Ophthalmol Vis Sci199940361963010067965
   PubMed Web of Science ®Google Scholar
• DebbaschCBrignoleFPisellaPJWarnetJMRatPBaudouinCQuaternary ammoniums and other preservatives’ contribution in oxidative stress and apoptosis on Chang conjunctival cellsInvest Ophthalmol Vis Sci200142364265211222522
   PubMed Web of Science ®Google Scholar
• AyakiMIwasawaACytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell linesClin Ophthalmol2010491992420823934
   PubMedGoogle Scholar
• YeeRWNorcomEGZhaoXCComparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture systemAdv Ther200623451151917050493
   PubMed Web of Science ®Google Scholar
• AmmarDANoeckerRJKahookMYEffects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cellsAdv Ther2010271183784520931366
   PubMed Web of Science ®Google Scholar
• GuenounJMBaudouinCRatPPaulyAWarnetJMBrignole-BaudouinFIn vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cellsInvest Ophthalmol Vis Sci200546124594459916303954
   PubMed Web of Science ®Google Scholar
• EpsteinSPChenDAsbellPAEvaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cellsJ Ocul Pharmacol Ther200925541542419857103
   PubMed Web of Science ®Google Scholar
• PaulyABrignole-BaudouinFLabbeALiangHWarnetJMBaudouinCNew tools for the evaluation of toxic ocular surface changes in the ratInvest Ophthalmol Vis Sci200748125473548318055795
   PubMed Web of Science ®Google Scholar
• KahookMYNoeckerRQuantitative analysis of conjunctival goblet cells after chronic application of topical dropsAdv Ther200825874375118670744
   PubMed Web of Science ®Google Scholar
• BaudouinCde LunardoCShort-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteersBr J Ophthalmol199882139429536878
   PubMed Web of Science ®Google Scholar
• YalvacISGedikogluGKaragozYEffects of antiglaucoma drugs on ocular surfaceActa Ophthalmol Scand19957332462487493237
   PubMedGoogle Scholar
• AriciMKAriciDSTopalkaraAGulerCAdverse effects of topical antiglaucoma drugs on the ocular surfaceClin Experiment Ophthalmol200028211311710933774
   PubMed Web of Science ®Google Scholar
• HerrerasJMPastorJCCalongeMAsensioVMOcular surface alteration after long-term treatment with an antiglaucomatous drugOphthalmology1992997108210881495787
   PubMed Web of Science ®Google Scholar
• MartoneGFrezzottiPTosiGMAn in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphologyAm J Ophthalmol20091474725735.e119181302
   PubMed Web of Science ®Google Scholar
• KatzLJTwelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertensionJ Glaucoma200211211912611912359
   PubMed Web of Science ®Google Scholar
• MundorfTWilliamsRWhitcupSFelixCBatoosinghAA 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertensionJ Ocul Pharmacol Ther2003191374412648302
   PubMed Web of Science ®Google Scholar
• CodlingCEMaillardJYRussellADAspects of the antimicrobial mechanisms of action of a polyquaternium and an amidoamineJ Antimicrob Chemother20035151153115812697638
   PubMed Web of Science ®Google Scholar
• UbelsJLClousingDPVan HaitsmaTAPre-clinical investigation of the efficacy of an artificial tear solution containing hydroxypropyl-guar as a gelling agentCurr Eye Res200428643744415512952
   PubMed Web of Science ®Google Scholar
• LabbeAPaulyALiangHComparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental studyJ Ocul Pharmacol Ther200622426727816910868
   PubMed Web of Science ®Google Scholar
• LewisRAKatzGJWeissMJTravoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacyJ Glaucoma20071619810317224758
   PubMed Web of Science ®Google Scholar
• KarampatakisVKaramitsosASkriapaAPastiadisGComparison between normal values of 2- and 5-minute Schirmer test without anesthesiaCornea201029549750120299972
   PubMed Web of Science ®Google Scholar
• KhanalSTomlinsonAMcFadyenADiaperCRamaeshKDry eye diagnosisInvest Ophthalmol Vis Sci20084941407141418385057
   PubMed Web of Science ®Google Scholar
• NicholsKKMitchellGLZadnikKThe repeatability of clinical measurements of dry eyeCornea200423327228515084861
   PubMed Web of Science ®Google Scholar
• PatelSMurrayDMcKenzieAShearerDSMcGrathBDEffects of fluorescein on tear breakup time and on tear thinning timeAm J Optom Physiol Opt19856231881903985110
   PubMedGoogle Scholar
• HorsleyMBKahookMYEffects of prostaglandin analog therapy on the ocular surface of glaucoma patientsClin Ophthalmol2009329129519668581
   PubMedGoogle Scholar
• AfonsoAAMonroyDSternMEFeuerWJTsengSCPflugfelderSCCorrelation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptomsOphthalmology1999106480381010201606
   PubMed Web of Science ®Google Scholar
• MacriAPflugfelderSCorrelation of the Schirmer 1 and fluorescein clearance tests with the severity of corneal epithelial and eyelid diseaseArch Ophthalmol2000118121632163811115257
   PubMedGoogle Scholar
• LiuZPflugfelderSCCorneal surface regularity and the effect of artificial tears in aqueous tear deficiencyOphthalmology1999106593994310328393
   PubMed Web of Science ®Google Scholar
• de PaivaCSLindseyJLPflugfelderSCAssessing the severity of keratitis sicca with videokeratoscopic indicesOphthalmology200311061102110912799233
   PubMed Web of Science ®Google Scholar
• Alonso-CaneiroDIskanderDRCollinsMJAssessment of tear film surface quality using dynamic-area high-speed videokeratoscopyIEEE Trans Biomed Eng20095651473148119174338
   PubMed Web of Science ®Google Scholar
• SzczesnaDHAlonso-CaneiroDIskanderDRReadSACollinsMJPredicting dry eye using noninvasive techniques of tear film surface assessmentInvest Ophthalmol Vis Sci201152275175620881295
   PubMed Web of Science ®Google Scholar
• KojimaTMatsumotoYDogruMTsubotaKThe application of in vivo laser scanning confocal microscopy as a tool of conjunctival in vivo cytology in the diagnosis of dry eye ocular surface diseaseMol Vis2010162457246421139693
   PubMed Web of Science ®Google Scholar
• Benitez-Del-CastilloJMAcostaMCWassfiMARelation between corneal innervation with confocal microscopy and corneal sensitivity with noncontact esthesiometry in patients with dry eyeInvest Ophthalmol Vis Sci200748117318117197530
   PubMed Web of Science ®Google Scholar
• BaudouinCLiangHBremond-GignacDCCR 4 and CCR 5 expression in conjunctival specimens as differential markers of T(H)1/T(H)2 in ocular surface disordersJ Allergy Clin Immunol2005116361461916159632
   PubMed Web of Science ®Google Scholar
• SullivanBDWhitmerDNicholsKKAn objective approach to dry eye disease severityInvest Ophthalmol Vis Sci201051126125613020631232
   PubMed Web of Science ®Google Scholar
• McMonniesCWHoAResponses to a dry eye questionnaire from a normal populationJ Am Optom Assoc19875875885913668156
   PubMedGoogle Scholar
• McMonniesCWHoAPatient history in screening for dry eye conditionsJ Am Optom Assoc19875842963013584792
   PubMedGoogle Scholar
• BaudouinCCreuzot-GarcherCHoang-XuanTCreating a specific diagnostic and quality-of-life questionnaire for patients with ocular surface diseaseJ Fr Ophtalmol2003262119130 French12660584
   PubMed Web of Science ®Google Scholar
• SchiffmanRMChristiansonMDJacobsenGHirschJDReisBLReliability and validity of the Ocular Surface Disease IndexArch Ophthalmol2000118561562110815152
   PubMedGoogle Scholar
• OzcuraFAydinSHelvaciMROcular surface disease index for the diagnosis of dry eye syndromeOcul Immunol Inflamm200715538939317972223
   PubMed Web of Science ®Google Scholar
• MillerKLWaltJGMinkDRMinimal clinically important difference for the ocular surface disease indexArch Ophthalmol201012819410120065224
   PubMedGoogle Scholar
• VersuraPProfazioVCamposECPerformance of tear osmolarity compared to previous diagnostic tests for dry eye diseasesCurr Eye Res201035755356420597641
   PubMed Web of Science ®Google Scholar
• ValenteCIesterMCorsiERolandoMSymptoms and signs of tear film dysfunction in glaucomatous patientsJ Ocul Pharmacol Ther201127328128521557633
   PubMed Web of Science ®Google Scholar
• WalkerPMLaneKJOuslerGW3rdAbelsonMBDiurnal variation of visual function and the signs and symptoms of dry eyeCornea201029660761220458235
   PubMed Web of Science ®Google Scholar
• BourcierTAcostaMCBorderieVDecreased corneal sensitivity in patients with dry eyeInvest Ophthalmol Vis Sci20054672341234515980220
   PubMed Web of Science ®Google Scholar
• HenryJCPeaceJHStewartJAStewartWCEfficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapyClin Ophthalmol20082361362119668762
   PubMedGoogle Scholar
• KatzGSpringsCLCravenERMontecchi-PalmerMOcular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprostClin Ophthalmol201041253126121151330
   PubMedGoogle Scholar